Patient charities ink deals to wrap up the Justice Department's co-pay kickback probe

Close-up of two people shaking hands with other people in the background
Two patient co-pay charities are settling with the feds to escape patient kickback allegations. (Pixabay)

An industrywide federal probe into drugmakers' use of charitable foundations to allegedly offer kickbacks for prescriptions of its drugs has netted some big fish in the last two years. Now, for the first time, two of the charities involved in the case have agreed to settle. 

Good Days and Patient Access Network Foundation will shell out a combined $6 million to close U.S. Department of Justice claims they operated as pharma front funds to effectively pay patients to take their drugs. 

Good Days President Clorinda Walley said in a statement the foundation would "continue to comply with all regulatory requirements surrounding charitable copay assistance programs and we welcome further clarity and (Office of the Inspector General) guidance to ensure we can continue to put patients in need first."


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

As part of the deal, Good Days agreed to pay $2 million while PAN Foundation will shell out $4 million. Neither foundation admitted wrongdoing. 

RELATED: Mallinckrodt hit with new kickback charges same day as $15.4M settlement with feds

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.